OHRP Underfunding and 45 CFR 46 Oversight Risk

The Federal regulations at 45 CFR 46—the Common Rule—still set the baseline for HHS-supported human subjects research. In 2025–2026, deep staffing cuts at the Office for Human Research Protections (OHRP) raised a practical question: who enforces the rulebook when the federal referee is short-handed?

Key Takeaways

45 CFR 46 remains the Common Rule framework for IRB review, informed consent, and institutional assurances on HHS-supported research.
JAMA commentary in 2025 warned that HHS reductions left OHRP at roughly one-quarter of a prior ~40-person peak and that SACHRP was terminated.
Sponsors should assume slower federal guidance and fewer compliance investigations, which shifts day-to-day burden onto IRBs and institutional HRPPs.
FDA human-subjects expectations for IND trials remain separate; do not confuse OHRP Common Rule coverage with FDA bioresearch monitoring.

What do the Federal regulations at 45 CFR 46 require?

The Federal regulations at 45 CFR 46, often called the Common Rule, require institutional assurances, IRB review, and informed consent for covered HHS-supported human subjects research. HHS explains OHRP’s role in overseeing those protections on the HHS OHRP site.

For a durable secondary summary of why federal ethics capacity matters when institutions are strained, see the JAMA Viewpoint on preserving research ethics oversight.

How severe are the reported OHRP staffing cuts?

Peer-reviewed commentary describes OHRP as historically underresourced, then further reduced during 2025 HHS workforce cuts to about one-quarter of a prior peak near 40 staff. The Secretary’s Advisory Committee on Human Research Protections (SACHRP) was also terminated, removing a long-running public advisory channel on hard ethics questions.

Exact headcounts fluctuate and are not always published in real time. Treat “about one-quarter of peak” as the best published estimate in JAMA, not as a live roster.

Why does thin OHRP capacity matter for pharma sponsors?

OHRP designs policy, investigates noncompliance allegations at assured institutions, and educates IRBs. With fewer staff, sponsors should expect longer waits for formal guidance, fewer for-cause investigations, and more variability across institutions that fill the vacuum with local rules.

IRB turnaround and local policy creep may increase
Allegation investigations may queue longer
Novel AI, data, and decentralized designs get less centralized advice

How should IRBs and HRPPs respond in 2026?

Double-check consent templates against the Common Rule elements, document reliance agreements carefully, and keep training current using NIH human-subjects resources such as the NIH human subjects research policy hub. Do not wait for OHRP to notice gaps first.

Common Rule vs FDA oversight: keep the lanes clear

OHRP’s Common Rule authority covers HHS-supported research. FDA bioresearch monitoring and IRB rules for IND/IDE trials are a parallel track. A protocol can trigger both. Staffing stress at OHRP does not relax FDA inspection risk for commercial sponsors.

What remains unproven about trial-safety impact?

Published commentary argues risk is rising; it does not prove a quantified increase in participant harm events tied solely to OHRP headcount. Avoid claiming a specific percentage rise in protocol violations unless a primary dataset shows it.

Action list for clinical operations and BD diligence

In diligence memos, note IRB capacity, recent FDA BIMO history, and whether a site’s HRPP is absorbing work that once relied on federal Q&A. For consortium trials, assign an ethics lead who tracks both Common Rule and FDA requirements. Budget for longer IRB negotiation cycles in 2026.

Operational signals sponsors can monitor without new OHRP memos

Watch institutional IRB meeting minutes for sudden local policy additions, especially around AI secondary research, data lakes, and decentralized consent. When federal FAQs stall, institutions invent local rules. That creates multi-site inconsistency that slows startup more than a single federal delay would.

Also track NIH and HHS budget justifications for any restoration of OHRP FTEs. A line-item rebound would matter more than another think-piece. Until then, assume education requests and determination letters take longer than historical norms from 2018–2023.

For inspection readiness, keep FDA BIMO binders current even on NIH-funded academic arms. Mixed funding streams are common in 2026 platform trials, and “OHRP is short-staffed” is not a defense in an FDA Form 483 response.

Related NovaPharma coverage

Frequently Asked Questions

What are the Federal regulations at 45 CFR 46?

They are the HHS Common Rule requirements for protecting human subjects in covered research, including IRB review, informed consent, and institutional assurances overseen by OHRP.

Why is OHRP underfunding a 2026 issue for sponsors?

Published JAMA commentary describes deep 2025 staffing cuts that left OHRP far below historical peak capacity and terminated SACHRP, which can slow guidance and compliance investigations.

Does OHRP understaffing remove FDA trial obligations?

No. FDA human-subjects and bioresearch monitoring rules for IND trials remain in force. Sponsors must still meet FDA expectations even if OHRP capacity is constrained.